A new infographic demonstrates how prioritizing patient support enables drug developers to navigate challenges across every stage of clinical research.
Obesity is a pervasive global health challenge impacting more than one billion people—and is expected to double in the next five years. GLP-1 receptor agonists and other anti-obesity medications (AOMs) represent life-changing hope. But finding treatment-naïve patients to participate in trials will become increasingly difficult and comorbidity inclusion criteria will narrow. Meanwhile, longstanding challenges with retention persist.
To overcome these obstacles, sponsors must prioritize patient engagement and support so that participants feel more like “co-pilots” and less like research subjects during the trial journey. A new infographic demonstrates how this model enables drug developers to navigate challenges across every stage of clinical research. It shows how achieving this entails:
- Incorporating the patient voice into the trial design and requirements
- Understanding the lived experiences of participants
- Consistently providing value beyond the Investigational Product (IP)
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and IQVIA
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and IQVIA
